Your end-of-week digest highlighting the most important developments in biotech, medtech, and pharma. The BioMed Nexus Weekly Roundup brings together the biggest approvals, trial readouts, financing moves, deals, and industry trends so you always see the full picture.
Three stories from the weekend reshape their respective markets. The Supreme Court ruled to maintain mifepristone access while litigation continues, resolving the near-term regulatory uncertainty
Biopharma M&A reached $84 billion in Q1 2026, the strongest start to a year since 2019, according to Dealogic data cited by Reuters. If the
India’s largest drugmaker just made the biggest outbound pharma acquisition in the country’s history. Sun Pharmaceutical Industries announced a definitive agreement to acquire Organon for
Kailera Therapeutics just told you everything you need to know about the obesity market in April 2026. An 18-month-old company built around Chinese-licensed GLP-1 assets
The FDA issued a second complete response letter for Replimune’s RP1 in advanced melanoma on Friday, and the fallout is immediate. CEO Sushil Patel said
Last week was defined by regulatory milestones and market reality checks. The FDA approved Ascendis Pharma’s YUVIWEL (navepegritide) on Friday, the second achondroplasia therapy and
Last week delivered a regulatory reckoning that reshaped biotech valuation frameworks: the FDA rejected Disc Medicine’s bitopertin despite meeting its primary endpoint, issued a Refusal-to-File
Cytokinetics wins FDA approval for Myqorzo (aficamten) late Friday validating next-generation cardiac myosin inhibitor class and setting up heavyweight 2026 commercial battle with Bristol Myers
BioCryst pediatric Orladeyo approved but stock fades flat (-0.1%) on “sell the news” despite $200M incremental revenue potential, Innoviva Zoliflodacin (Nuzolvence) wins first-in-class oral gonorrhea
Vertex Casgevy achieves 100% efficacy in pediatric sickle cell, Arcellx Anito-cel demonstrates cleaner safety profile challenging Carvykti, Lilly’s Jaypirca wins head-to-head vs. Imbruvica, Structure oral
